A fully implantable device for diffuse insulin delivery at extraperitoneal site for physiological treatment of type 1 diabetes.
暂无分享,去创建一个
M. Vix | N. Jeandidier | S. Sigrist | Charles-Thibault Burcez | J. Magisson | A. Sassi | Aram Kobalyan | Richard Bouaoun
[1] Eyal Dassau,et al. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control‐based fully‐automated artificial pancreas in patients with type 1 diabetes: a pilot study , 2017, Diabetes, obesity & metabolism.
[2] Spencer P Lake,et al. Mechanical properties of the abdominal wall and biomaterials utilized for hernia repair. , 2017, Journal of the mechanical behavior of biomedical materials.
[3] R. Hovorka,et al. Finding the right route for insulin delivery – an overview of implantable pump therapy , 2017, Expert opinion on drug delivery.
[4] G. Kenter,et al. The histophysiology and pathophysiology of the peritoneum. , 2017, Tissue & cell.
[5] A. Deshmukh. Insulin-stimulated glucose uptake in healthy and insulin-resistant skeletal muscle , 2016, Hormone molecular biology and clinical investigation.
[6] S. Dal,et al. Portal or subcutaneous insulin infusion: efficacy and impact on liver inflammation , 2015, Fundamental & clinical pharmacology.
[7] R·布奥,et al. A chamber for encapsulating secreting cells , 2014 .
[8] M. Diamond,et al. The biology of adhesion formation in the peritoneal cavity. , 2014, Seminars in pediatric surgery.
[9] R. Gans,et al. Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia , 2014, Clinical endocrinology.
[10] H. Bilo,et al. Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up , 2014, BMC Endocrine Disorders.
[11] Jinzeng Yang. Enhanced skeletal muscle for effective glucose homeostasis. , 2014, Progress in molecular biology and translational science.
[12] E. Bonifacio,et al. Transplantation of human islets without immunosuppression , 2013, Proceedings of the National Academy of Sciences.
[13] R. Patel,et al. Applied peritoneal anatomy. , 2013, Clinical radiology.
[14] H. Bilo,et al. Complications of continuous intraperitoneal insulin infusion with an implantable pump. , 2012, World journal of diabetes.
[15] M. Meurisse,et al. Pathophysiology and prevention of postoperative peritoneal adhesions. , 2011, World journal of gastroenterology.
[16] S. Raptis,et al. Insulin effects in muscle and adipose tissue. , 2011, Diabetes research and clinical practice.
[17] M. Wallwiener,et al. Intraperitoneal adhesions--an ongoing challenge between biomedical engineering and the life sciences. , 2011, Journal of biomedical materials research. Part A.
[18] A. Penfornis,et al. Evolution of devices in diabetes management. , 2011, Diabetes technology & therapeutics.
[19] E. Renard,et al. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion , 2009, Diabetes, obesity & metabolism.
[20] R. Gans,et al. Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes , 2009, Diabetes Care.
[21] H. Bilo,et al. Surgical aspects and complications of continuous intraperitoneal insulin infusion with an implantable pump , 2008, Langenbeck's Archives of Surgery.
[22] E. Barrett,et al. Hyperinsulinemia Rapidly Increases Human Muscle Microvascular Perfusion but Fails to Increase Muscle Insulin Clearance , 2007, Diabetes.
[23] E Renard,et al. Implantable insulin pumps. A position statement about their clinical use. , 2007, Diabetes & metabolism.
[24] M. Flessner,et al. The transport barrier in intraperitoneal therapy. , 2005, American journal of physiology. Renal physiology.
[25] P. Helms,et al. The Influence of Peritoneal Surface Area on Dialysis Adequacy , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[26] H Gin,et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. , 2003, Diabetes & metabolism.
[27] S. Yamamoto,et al. Variation of serum alpha2-macroglobulin concentration in healthy rats and rats inoculated with Staphylococcus aureus or subjected to surgery. , 2001, Comparative medicine.
[28] V. Karsten,et al. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. , 2001, Diabetes care.
[29] M. Matsuhisa,et al. Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment. , 2000, Metabolism: clinical and experimental.
[30] P. Oskarsson,et al. Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. , 2000, Diabetes & metabolism.
[31] M. Tauber,et al. Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM , 1996, Diabetologia.
[32] J. Skyler,et al. Splanchnic and systemic absorption of intraperitoneal insulin using a new double-tracer method. , 1994, The American journal of physiology.
[33] A. Caumo,et al. Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects. , 1993, The Journal of clinical endocrinology and metabolism.
[34] R. Bergman,et al. Determination of Portal Insulin Absorption From Peritoneum via Novel Nonisotopic Method , 1990, Diabetes.
[35] E. A. Vaughn,et al. The kinetics of peritoneal insulin absorption. , 1981, Metabolism: clinical and experimental.
[36] R. Eaton,et al. The peritoneal absorption of insulin in diabetic man: a potential site for a mechanical insulin delivery system. , 1979, Metabolism: clinical and experimental.
[37] C. Kjellstrand,et al. Intraperitoneal Insulin for Control of Blood Sugar in Diabetic Patients during Peritoneal Dialysis , 1971, British medical journal.